Extracellular Vesicles: The Invisible Heroes and Villains of COVID-19 Central Neuropathology

被引:1
|
作者
Chang, Haiqing [1 ]
Chen, Erya [1 ]
Hu, Yi [2 ]
Wu, Lining [1 ]
Deng, Liyun [1 ]
Ye-Lehmann, Shixin [3 ]
Mao, Xiaobo [4 ]
Zhu, Tao [1 ]
Liu, Jin [1 ]
Chen, Chan [1 ]
机构
[1] Sichuan Univ, West China Hosp, Natl Local Joint Engn Res Ctr Translat Med Anesthe, Lab Anesthesia & Crit Care Med,Dept Anesthesiol, Chengdu 610041, Sichuan, Peoples R China
[2] Xi An Jiao Tong Univ, Honghui Hosp, Dept Cardiol, Xian 710049, Peoples R China
[3] Dis & Hormones Nervous Syst Univ Paris Scalay, Bicetre Hosptial Bat, Gregory Pincus 80 Rue Gal Leclerc, F-94276 Le Kremlin Bicetre, France
[4] Johns Hopkins Univ, Sch Med, Dept Neurol, Inst Cell Engn, Baltimore, MD 21218 USA
基金
中国国家自然科学基金;
关键词
COVID-19; central nervous system; extracellular vesicles; neuropathology; SARS-CoV-2; MESENCHYMAL STEM-CELLS; CENTRAL-NERVOUS-SYSTEM; CREUTZFELDT-JAKOB-DISEASE; DRUG-DELIVERY VEHICLES; PARKINSONS-DISEASE; ISCHEMIC-STROKE; CHOROID-PLEXUS; SARS-COV-2; NEUROTROPISM; ALZHEIMERS-DISEASE; PROTEOMIC ANALYSIS;
D O I
10.1002/advs.202305554
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Acknowledging the neurological symptoms of COVID-19 and the long-lasting neurological damage even after the epidemic ends are common, necessitating ongoing vigilance. Initial investigations suggest that extracellular vesicles (EVs), which assist in the evasion of the host's immune response and achieve immune evasion in SARS-CoV-2 systemic spreading, contribute to the virus's attack on the central nervous system (CNS). The pro-inflammatory, pro-coagulant, and immunomodulatory properties of EVs contents may directly drive neuroinflammation and cerebral thrombosis in COVID-19. Additionally, EVs have attracted attention as potential candidates for targeted therapy in COVID-19 due to their innate homing properties, low immunogenicity, and ability to cross the blood-brain barrier (BBB) freely. Mesenchymal stromal/stem cell (MSCs) secreted EVs are widely applied and evaluated in patients with COVID-19 for their therapeutic effect, considering the limited antiviral treatment. This review summarizes the involvement of EVs in COVID-19 neuropathology as carriers of SARS-CoV-2 or other pathogenic contents, as predictors of COVID-19 neuropathology by transporting brain-derived substances, and as therapeutic agents by delivering biotherapeutic substances or drugs. Understanding the diverse roles of EVs in the neuropathological aspects of COVID-19 provides a comprehensive framework for developing, treating, and preventing central neuropathology and the severe consequences associated with the disease. On the one hand, EVs aid SARS-CoV-2 invasion in the nervous system. And the pro-inflammatory, pro-coagulant contents of EVs may drive lead to neuroinflammation and cerebral thrombosis in COVID-19 neurological complications. On the other hand, EVs are potential candidates for prevention and treatment of COVID-19 central neuropathology due to their homing properties, low immunogenicity, and ability to freely cross the blood-brain barrier.image
引用
收藏
页数:28
相关论文
共 50 条
  • [31] Evaluation of extracellular vesicles as noninvasive early predictive markers for severe COVID-19
    Murillo, P. A. Martinez
    Ravi, M.
    Eriksson, K.
    Adapa, S.
    Schildgen, O.
    Merten, M. L.
    Ghiran, I.
    Karagiannidis, C.
    Krebs, P.
    Kressler, D.
    Stumpe, M.
    Jiang, R.
    Mantel, P. Y.
    SWISS MEDICAL WEEKLY, 2023, 153 : 5S - 5S
  • [32] Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19
    Campello, Elena
    Radu, Claudia Maria
    Simion, Chiara
    Spiezia, Luca
    Bulato, Cristiana
    Gavasso, Sabrina
    Tormene, Daniela
    Perin, Nicola
    Turatti, Giacomo
    Simioni, Paolo
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 9
  • [33] Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment
    Yuling Huang
    Xin Li
    Lina Yang
    Stem Cell Research & Therapy, 13
  • [34] COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles
    Richard C. Becker
    Travis Sexton
    Susan Smyth
    Journal of Thrombosis and Thrombolysis, 2021, 52 : 1010 - 1019
  • [35] Extracellular vesicles and angiotensin-converting enzyme 2 in COVID-19 disease
    Liu, Yu
    Kasper, Robert j.
    Choi, Natalie j. s.
    BIOCELL, 2024, 48 (01) : 1 - 8
  • [36] Extracellular vesicles in plasma and cerebrospinal fluid in patients with COVID-19 and neurological symptoms
    Taxiarchis, Apostolos
    Bellander, Bo-Michael
    Antovic, Jovan
    Soutari, Nida
    Virhammar, Johan
    Kumlien, Eva
    Karakoyun, Can
    Rostami, Elham
    Antovic, Aleksandra
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2024, 46 (01) : 42 - 49
  • [37] Extracellular Vesicles as a Translational Approach for the Treatment of COVID-19 Disease: An Updated Overview
    Serretiello, Enrica
    Ballini, Andrea
    Smimmo, Annafrancesca
    Acunzo, Marina
    Raimo, Mariarosaria
    Cantore, Stefania
    Di Domenico, Marina
    VIRUSES-BASEL, 2023, 15 (10):
  • [38] Emerging roles of extracellular vesicles in COVID-19, a double-edged sword?
    Xia, Xiaohuan
    Yuan, Ping
    Liu, Yihan
    Wang, Yi
    Cao, Weijun
    Zheng, Jialin C.
    IMMUNOLOGY, 2021, 163 (04) : 416 - 430
  • [39] Exploiting Extracellular Vesicles Strategies to Modulate Cell Death and Inflammation in COVID-19
    Bortot, Barbara
    Romani, Arianna
    Ricci, Giuseppe
    Biffi, Stefania
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [40] Approximations to Diagnosis and Therapy of COVID-19 in Nervous Systems Using Extracellular Vesicles
    Rojas, Karen
    Verdugo-Molinares, Maritza G.
    Ochoa-Ruiz, Andrea G.
    Canales, Alejandro
    Reza-Zaldivar, Edwin E.
    Limon-Rojas, Areli
    Adriana Vallejo-Cardona, Alba
    PATHOGENS, 2022, 11 (12):